| 王可武,胡琴,凌林,等.奥沙利铂联合卡培他滨序贯替吉奥方案在 Ⅲ期胃癌术后辅助化疗中的疗效观察[J].安徽医药,2021,25(2):385-390. |
| 奥沙利铂联合卡培他滨序贯替吉奥方案在 Ⅲ期胃癌术后辅助化疗中的疗效观察 |
| Clinical study of XELOX sequential compound tegafur capsule regiment as adjuvant chemotherapy in the treatment of stage Ⅲ gastric cancer post radical gastrectomy |
| |
| DOI：10.3969/j.issn.1009-6469.2021.02.042. |
| 中文关键词: 胃肿瘤 化学疗法，辅助 替吉奥 奥沙利铂 卡培他滨 |
| 英文关键词: Stomach neoplasms Chemotherapy, adjuvant Compound tegafur capsule Oxaliplatin Capecitabine |
| 基金项目: |
|
| 摘要点击次数: 1640 |
| 全文下载次数: 576 |
| 中文摘要: |
| 目的观察奥沙利铂联合卡培他滨( XELOX)序贯替吉奥方案作为 Ⅲ期胃癌术后辅助化疗的有效性和安全性。方法回顾性分析 2012年 1月至 2016年 12月芜湖市第二人民医院 Ⅲ期胃癌术后辅助化疗病人 128例，分为观察组 58例和对照组 70例，观察组接受 XELOX序贯替吉奥方案，对照组仅接受 XELOX方案。比较两组肿瘤复发率、总生存时间( OS)、无复发生存时间( RFS)、无局部复发生存时间( LRRFS)和无远处转移生存时间( DMFS)并比较两组不良反应。结果观察组复发率低于对照组( 53.4%比 74.3%)差异有统计学意义( P < 0.05)。两组局部复发率比，较，差异无统计学意义( 18.9%比 20.0%，P> 0.05)，观察组远处转移的发生率，低于对照组( 31.3%比 48.6%，P < 0.05)。观察组和对照组的中位 OS分别为 53.9月和 46.2月( P <0.05)观察组和对照组的中位 RFS分别为 33.0个月、 27.3个月( P < 0.05)，观察组和对照组的中位 LRRFS分别为 30.2个月和30.5(P > 0.05)，观察组和对照组中位 DMFS分别为 32.3月和 24.8月(P < 0.05)，观察组的 DMFS高于对照组。无治疗相关性死亡病例，两组主要血液学不良反应发生率差异无统计学意义；两组色素沉着症发生率观察组比对照组发生率高( P < 个月，0.05)，两组其余非血液学毒性比较，均差异无统计学意义。结论 XELOX序贯替吉奥方案作为 Ⅲ期胃癌术后辅助化疗方案能降低远处转移的复发率、推迟复发的发生、延长病人的生存时间、不良反应可耐受，值得进一步研究。 |
| 英文摘要: |
| Objective To study the efficacy and safety of XELOX sequential compound tegafur capsule regiment as adjuvant chemotherapy for stage Ⅲgastric cancer post radical gastrectomy.Methods 128 patients with stage Ⅲgastric cancer after adjuvant chemotherapy were studied in the Second People's Hospital of Wuhu form January 2012 to December 2016, including 58 cases in study groupand 70 cases for control. The study group received the XELOX sequential compound tegafur capsule regiment, and the control group only received the XELOX regiment.The tumor recurrence rate, overall survival time (OS), relapse-free survival (RFS), locoregional recurrence-free survival (LRRFS) and distant metastasis-free survival (DMFS) were investigated, meanwhile, the occurrence of adverseevents between the two groups were also compared and analyzed.Results The recurrence rate of the study group was lower than that of the control group (53.4% vs.74.3%), indicating the significant difference between the two groups (P < 0.05), and the locoregional recurrence rate between the two groups shows no difference(18.9% vs. 20.0%, P > 0.05). Furthermore, the incidence of distant metastasis inthe study group, according to the datas, was lower than that in the control group with the rate 31.3% vs. 48.6% (P < 0.05). The median OS of the study group and the control group were 53.9 months and 46.2 months respectively (P < 0.05), coupled with median RFS between the two group were 33.0 months and 27.3 months respectively (P < 0.05).The median LRFFS of the study group and the control group were 30.2 months and 30.5 months respectively (P > 0.05) with the median DMFS were 32.3 months and 24.8 months of the two groups (P < 0.05). The DMFS of the study group was higher than that of the control group. Importantly, there were no treatment-related deaths in this study. There was no significant difference in the incidence of major hematologic adverse events between the two groups.The incidence of hyperpigmentation in the study groups was higher than that in the control group (P < 0.05). There were no statistical differences between the other non-hematologic adverse events.Conclusion Taken together, this study demonstrates that the XELOXsequential compound tegafur capsule regiment as a postoperative adjuvant chemotherapy for stage Ⅲgastric cancer can reduce the recurrence rate of distant metastasis, delay recurrence, prolong the survival time, and the adverse events can be tolerated, which indicatesthe worth for further study. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
